JAK2(V617F): Prevalence in a large Chinese hospital population - Wikidata - awgldk - TriplyDB

JAK2(V617F): Prevalence in a large Chinese hospital population

JAK2(V617F): Prevalence in a large Chinese hospital population

http://www.wikidata.org/entity/Q35615806

about

Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China.Stochastic dynamics and the evolution of mutations in stem cells Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.JAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases.Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.Development of a highly sensitive method for detection of JAK2V617F Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.A progenitor cell origin of myeloid malignancies Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study Targeting glutamine metabolism in myeloproliferative neoplasms.Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease.Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population.Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.Ethical considerations in genomic testing for hematologic disorders.JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms.Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective.Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.

P2860

Q27317353-29B657F3-7E34-4591-AC16-1E8DCA1B9765 Q28239018-21C4BFCC-C077-45A7-A247-3FC3E102023F Q28392728-CACBAB09-43C8-46DC-A82E-29BC6C44CFC8 Q30244631-8C31A1C8-C7DD-40C7-B46D-FA4F7DB81AD1 Q31017219-23450BC9-AADF-4875-B2CF-F4ABC458BC3C Q33813824-5C913371-AEA4-4D30-B222-B959E0615E40 Q33843882-F6DB3A34-553F-4705-84DB-B32C98C01B57 Q34375134-B49F6C52-336E-468D-BB5F-A6EA09817E35 Q34547493-511C5D49-CB99-44BF-9A3B-D70E45F95DF5 Q34612649-E4C56978-2C65-4220-A4A2-3EC0E6B5512C Q34687245-70C264E8-8CCB-4154-912E-DFB62062BDBC Q35521645-ACE52F93-BB02-4080-923F-965CFA79F86B Q35643476-C9A33C24-098B-47DF-BFF4-5A072221A1C5 Q36036299-2464AC63-D6ED-4F38-A614-32841774CB3B Q36248587-0A23395F-289C-4BE8-8EF1-E4E6B4431654 Q36261941-6A39A212-7BC3-495B-9BB0-C5106CD6E04C Q36306467-F1C25147-8EF4-4B9B-9F00-71A83D949394 Q36374813-CC31BC6B-E1A6-47C3-BE3E-66F82BAB6F91 Q36658043-60296331-6724-40D8-A8E3-063BACEBB957 Q37209108-9512E4DA-5022-42A2-8CB4-8C5A09CEB95C Q37250169-A009ACB1-422F-4B47-8017-2AB5C71FBF75 Q37284926-7F5E7720-7992-48AC-B695-2A0CE980448D Q37377284-D9AEA9C7-0BB8-41DC-B54C-4A9481D0F241 Q38132817-DD027643-9B07-412C-A0BC-3BB15C91177E Q38816384-94E4F3FD-0744-462A-91A4-308CFE2A41F9 Q38830536-93BB6CAC-4CD5-4532-A5CE-09BF7DE77B73 Q38847693-3A0DC5B8-4A55-4E53-B65F-1C72365C3C8A Q39108026-8F447ACA-E3BB-4409-A629-CB76BDA3CAC9 Q39276259-69B79966-C070-43DA-859F-F5E0E94B3FB9 Q39309957-BA4445B2-6FFA-456C-93CC-DFDB5AB3CA18 Q39363424-391A4D14-368A-4E2C-8C30-728A2508BFF2 Q41499758-8D011BBF-330D-4852-9F58-94C2405E5937 Q41902113-F3EC4818-A106-4FE3-8063-16B6D8E0A259 Q42062133-2C65A22C-8920-4FBF-A0BE-B6E67426C30E Q42870221-869F3FD6-69DA-47A5-9EE9-D765F1D09FDE Q43979129-146893C1-CB9B-4407-AA65-75C784CF8588 Q44265728-4C8A3131-1C28-49CB-9DA5-3C49784FE878 Q44345261-DB5E3AAD-2B8C-4B0A-A684-9C0D5A6A9A59 Q44985081-A5C0FF0A-1E68-49C6-BA0E-33002EF55351 Q45038631-9B64F19B-BA79-4F91-BE76-E94341DAF3C2

P2860

JAK2(V617F): Prevalence in a large Chinese hospital population

http://www.wikidata.org/entity/Q35615806

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

JAK2(V617F): Prevalence in a large Chinese hospital population

@ast

JAK2(V617F): Prevalence in a large Chinese hospital population

@en

type

label

JAK2(V617F): Prevalence in a large Chinese hospital population

@ast

JAK2(V617F): Prevalence in a large Chinese hospital population

@en

prefLabel

JAK2(V617F): Prevalence in a large Chinese hospital population

@ast

JAK2(V617F): Prevalence in a large Chinese hospital population

@en

P1433

Q35615806-0C32A9B2-FD6F-4493-9D44-A3BB96385B74

P1476

Q35615806-D1FB319D-C757-41FF-A88E-52FE8A9D8BCE

P2093

Q35615806-079DFEA4-6869-40B0-A55C-05EA456C9148

Q35615806-1D650EBF-7C5E-4888-ABA8-BE76187767C0

Q35615806-2979109E-BB5F-4AF9-85B0-AE3CFA1F63EF

Q35615806-920F2883-373D-465B-8056-FED640000A79

Q35615806-D6FF2699-14EB-43B7-B530-7293900A5583

Q35615806-F8743C47-03E6-4479-851C-8C7A67E72515

Q35615806-FBB58B97-17C7-4B59-8172-EAE919F76964

P2860

Q35615806-04B6E913-B9BB-4ADE-BB62-43686E88F13A

Q35615806-13ECCC02-E87D-424D-B8CA-7A45C606F94D

Q35615806-18889632-BFC3-4E3E-B9F4-9370D38F9613

Q35615806-188F629D-CB7B-48E0-BB8B-634389B61131

Q35615806-32D06B0E-6C27-4A61-BB10-3E4337A966D9

Q35615806-38B26B33-BBA2-48D4-850F-A89FC2EAC798

Q35615806-3E6CFE7D-78A1-4DBB-A87A-B163B40F0642

Q35615806-4193DA92-8E22-49A8-ACA3-BB9EF3BBFBFE

Q35615806-495AA618-236D-4653-9D90-705B41F173AF

Q35615806-4DEFDBCE-6237-4433-9AC4-EB9ECEA0595A

P304

Q35615806-670F908C-B8D5-4ED4-910E-CFD08CE2C08B

P31

Q35615806-AAD326A7-E6D8-4297-8A71-BF604C6FE3A8

P356

Q35615806-EA8D8EF0-5D93-4B13-949D-E9AC8030D25F

P407

Q35615806-70DE6810-F310-4457-9164-9C6382CF2C4A

P433

Q35615806-C70D2545-E92C-4698-9E17-90D8C47BCB96

P478

Q35615806-14792C00-06BF-4807-8733-F8EEE467CC3E

P50

Q35615806-3F8DC67E-5F72-45E5-B724-987485744AC1

P577

Q35615806-B3DB77ED-F50A-4090-9760-C1CE55A751D2

P5875

Q35615806-9AF2E058-F2F4-4A2A-82E2-35297C1FE750

P698

Q35615806-7F101AA8-7936-4979-85BF-5BDEA58263C4

P932

Q35615806-502A6326-10B6-42FF-9C3E-661D42E6253A

P356

BLOOD-2006-03-009472

P1433

P1476

JAK2(V617F): Prevalence in a large Chinese hospital population

@en

P2093

Jian Luo

http://www.w3.org/2001/XMLSchema#string

Qi Zhang

http://www.w3.org/2001/XMLSchema#string

Qingshan Li

http://www.w3.org/2001/XMLSchema#string

Sanford B Krantz

http://www.w3.org/2001/XMLSchema#string

Xueqi Fu

http://www.w3.org/2001/XMLSchema#string

Xuesong Xu

http://www.w3.org/2001/XMLSchema#string

Zhizhuang Joe Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Oncogenic kinase signalling

Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

P304

339-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-03-009472

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6843222

http://www.w3.org/2001/XMLSchema#string

P698

16946305

http://www.w3.org/2001/XMLSchema#string

P932

1785080

http://www.w3.org/2001/XMLSchema#string